Filing Flows › Comparisons › EDIT vs RGNX
Editas Medicine vs Regenxbio: EDIT and RGNX compared
Editas Medicine is the larger company: $10.4M of revenue in its latest quarter (Q3 2026) against $9.2M for Regenxbio (Q3 2026). Editas Medicine is growing faster (+37% against -69% a year earlier). Editas Medicine is more profitable, with an operating margin of -234.3% against -387.8%.
Where the money goes: EDIT and RGNX
Editas Medicine (EDIT) · Q3 2026
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
Regenxbio (RGNX) · Q3 2026
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
| Editas Medicine (EDIT) | Regenxbio (RGNX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.4M | $9.2M |
| Revenue growth, Y/Y | +37% | -69% |
| Operating margin | -234.3% | -387.8% |
| Net earnings | −$23.4M | −$40.7M |
| Net margin | -225.7% | -444.6% |
| Operating cash flow | −$21.2M | $38.6M |
| Free cash flow | — | $38.4M |
Where the revenue comes from
Regenxbio
- License and Service: $5.2M (57%)
- Service: $3.9M (43%)
Questions
Which is bigger, Editas Medicine or Regenxbio?
Editas Medicine is the larger company: $10.4M of revenue in its latest quarter (Q3 2026) against $9.2M for Regenxbio (Q3 2026).
Is Editas Medicine or Regenxbio growing faster?
Editas Medicine is growing faster (+37% against -69% a year earlier).
Which is more profitable, Editas Medicine or Regenxbio?
Editas Medicine is more profitable, with an operating margin of -234.3% against -387.8%.
More: Editas Medicine earnings · how Editas Medicine makes money · Regenxbio earnings · how Regenxbio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.